JP2005053907A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005053907A5 JP2005053907A5 JP2004223680A JP2004223680A JP2005053907A5 JP 2005053907 A5 JP2005053907 A5 JP 2005053907A5 JP 2004223680 A JP2004223680 A JP 2004223680A JP 2004223680 A JP2004223680 A JP 2004223680A JP 2005053907 A5 JP2005053907 A5 JP 2005053907A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- epinastine
- pharmaceutical
- pharmaceutical composition
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- WHWZLSFABNNENI-UHFFFAOYSA-N epinastine Chemical compound C1C2=CC=CC=C2C2CN=C(N)N2C2=CC=CC=C21 WHWZLSFABNNENI-UHFFFAOYSA-N 0.000 claims description 27
- 150000003839 salts Chemical class 0.000 claims description 22
- 229960003449 epinastine Drugs 0.000 claims description 20
- 208000017520 skin disease Diseases 0.000 claims description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 239000002552 dosage form Substances 0.000 claims description 13
- -1 diphenylpyralin Chemical compound 0.000 claims description 9
- 238000011200 topical administration Methods 0.000 claims description 9
- 230000002265 prevention Effects 0.000 claims description 7
- 201000004624 Dermatitis Diseases 0.000 claims description 6
- 208000003251 Pruritus Diseases 0.000 claims description 6
- 229960002548 epinastine hydrochloride Drugs 0.000 claims description 6
- 206010020751 Hypersensitivity Diseases 0.000 claims description 5
- 239000013543 active substance Substances 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 4
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims description 3
- 208000024780 Urticaria Diseases 0.000 claims description 3
- 208000010668 atopic eczema Diseases 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 2
- 229960001340 histamine Drugs 0.000 claims 8
- ZZHLYYDVIOPZBE-UHFFFAOYSA-N Trimeprazine Chemical group C1=CC=C2N(CC(CN(C)C)C)C3=CC=CC=C3SC2=C1 ZZHLYYDVIOPZBE-UHFFFAOYSA-N 0.000 claims 4
- OJFSXZCBGQGRNV-UHFFFAOYSA-N carbinoxamine Chemical compound C=1C=CC=NC=1C(OCCN(C)C)C1=CC=C(Cl)C=C1 OJFSXZCBGQGRNV-UHFFFAOYSA-N 0.000 claims 4
- 229960000428 carbinoxamine Drugs 0.000 claims 4
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 claims 4
- 229960003291 chlorphenamine Drugs 0.000 claims 4
- 229960000520 diphenhydramine Drugs 0.000 claims 4
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 claims 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims 4
- MBUVEWMHONZEQD-UHFFFAOYSA-N Azeptin Chemical compound C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1 MBUVEWMHONZEQD-UHFFFAOYSA-N 0.000 claims 2
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 claims 2
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 claims 2
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 claims 2
- HOKDBMAJZXIPGC-UHFFFAOYSA-N Mequitazine Chemical compound C12=CC=CC=C2SC2=CC=CC=C2N1CC1C(CC2)CCN2C1 HOKDBMAJZXIPGC-UHFFFAOYSA-N 0.000 claims 2
- 206010040880 Skin irritation Diseases 0.000 claims 2
- UFLGIAIHIAPJJC-UHFFFAOYSA-N Tripelennamine Chemical compound C=1C=CC=NC=1N(CCN(C)C)CC1=CC=CC=C1 UFLGIAIHIAPJJC-UHFFFAOYSA-N 0.000 claims 2
- 229960003790 alimemazine Drugs 0.000 claims 2
- 208000030961 allergic reaction Diseases 0.000 claims 2
- 229960004574 azelastine Drugs 0.000 claims 2
- 229960002071 bepotastine Drugs 0.000 claims 2
- YWGDOWXRIALTES-NRFANRHFSA-N bepotastine Chemical compound C1CN(CCCC(=O)O)CCC1O[C@H](C=1N=CC=CC=1)C1=CC=C(Cl)C=C1 YWGDOWXRIALTES-NRFANRHFSA-N 0.000 claims 2
- 229960001803 cetirizine Drugs 0.000 claims 2
- 229960002881 clemastine Drugs 0.000 claims 2
- YNNUSGIPVFPVBX-NHCUHLMSSA-N clemastine Chemical compound CN1CCC[C@@H]1CCO[C@@](C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 YNNUSGIPVFPVBX-NHCUHLMSSA-N 0.000 claims 2
- 229960001140 cyproheptadine Drugs 0.000 claims 2
- JJCFRYNCJDLXIK-UHFFFAOYSA-N cyproheptadine Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2C=CC2=CC=CC=C21 JJCFRYNCJDLXIK-UHFFFAOYSA-N 0.000 claims 2
- 229960001971 ebastine Drugs 0.000 claims 2
- MJJALKDDGIKVBE-UHFFFAOYSA-N ebastine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(=O)CCCN1CCC(OC(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 MJJALKDDGIKVBE-UHFFFAOYSA-N 0.000 claims 2
- 229960000325 emedastine Drugs 0.000 claims 2
- KBUZBQVCBVDWKX-UHFFFAOYSA-N emedastine Chemical compound N=1C2=CC=CC=C2N(CCOCC)C=1N1CCCN(C)CC1 KBUZBQVCBVDWKX-UHFFFAOYSA-N 0.000 claims 2
- 229960003592 fexofenadine Drugs 0.000 claims 2
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 claims 2
- 229960004958 ketotifen Drugs 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 229960005042 mequitazine Drugs 0.000 claims 2
- 229960004114 olopatadine Drugs 0.000 claims 2
- JBIMVDZLSHOPLA-LSCVHKIXSA-N olopatadine Chemical compound C1OC2=CC=C(CC(O)=O)C=C2C(=C/CCN(C)C)\C2=CC=CC=C21 JBIMVDZLSHOPLA-LSCVHKIXSA-N 0.000 claims 2
- 229960002698 oxatomide Drugs 0.000 claims 2
- BAINIUMDFURPJM-UHFFFAOYSA-N oxatomide Chemical compound O=C1NC2=CC=CC=C2N1CCCN(CC1)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 BAINIUMDFURPJM-UHFFFAOYSA-N 0.000 claims 2
- 229960003910 promethazine Drugs 0.000 claims 2
- 230000036556 skin irritation Effects 0.000 claims 2
- 231100000475 skin irritation Toxicity 0.000 claims 2
- 229960000351 terfenadine Drugs 0.000 claims 2
- 229960003223 tripelennamine Drugs 0.000 claims 2
- 229960001128 triprolidine Drugs 0.000 claims 2
- CBEQULMOCCWAQT-WOJGMQOQSA-N triprolidine Chemical compound C1=CC(C)=CC=C1C(\C=1N=CC=CC=1)=C/CN1CCCC1 CBEQULMOCCWAQT-WOJGMQOQSA-N 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000000144 pharmacologic effect Effects 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 239000006208 topical dosage form Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 3
- 208000010201 Exanthema Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- SXDBWCPKPHAZSM-UHFFFAOYSA-M bromate Inorganic materials [O-]Br(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-M 0.000 description 1
- SXDBWCPKPHAZSM-UHFFFAOYSA-N bromic acid Chemical compound OBr(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03016681 | 2003-08-01 | ||
| EP03016681.3 | 2003-08-01 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005053907A JP2005053907A (ja) | 2005-03-03 |
| JP2005053907A5 true JP2005053907A5 (enExample) | 2007-09-13 |
| JP5021155B2 JP5021155B2 (ja) | 2012-09-05 |
Family
ID=34354409
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004223680A Expired - Lifetime JP5021155B2 (ja) | 2003-08-01 | 2004-07-30 | エピナスチンと１種以上のさらなる抗−ｈ１−ヒスタミン類との組合せを含む皮膚疾患治療用製薬組成物 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP5021155B2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2472499C2 (ru) * | 2007-06-08 | 2013-01-20 | Байер Конзюмер Кер АГ | Лекарственное средство, включающее комбинацию активных веществ, содержащую пантотеновую кислоту или ее производные, для лечения аллергических симптомов |
| JP2019043853A (ja) * | 2017-08-30 | 2019-03-22 | 旭化成株式会社 | 経皮吸収促進剤、経皮吸収促進助剤、及び経皮製剤 |
| WO2022138826A1 (ja) * | 2020-12-24 | 2022-06-30 | 参天製薬株式会社 | エピナスチン又はその塩を含有する塗布投与用医薬組成物 |
| WO2022138842A1 (ja) * | 2020-12-24 | 2022-06-30 | 参天製薬株式会社 | エピナスチン又はその塩と硫黄系抗酸化剤を含有する経皮投与用医薬組成物 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4563522B2 (ja) * | 1999-02-19 | 2010-10-13 | 豊也 加藤 | アレルギー疾患治療剤 |
| PE20020324A1 (es) * | 2000-10-06 | 2002-06-18 | Boehringer Ingelheim Int | Nuevas composiciones farmaceuticas que contienen epinastina y pseudoefedrina |
| US6827946B2 (en) * | 2001-12-05 | 2004-12-07 | Collegium Pharmaceutical, Inc. | Compositions containing both sedative and non-sedative antihistamines |
-
2004
- 2004-07-30 JP JP2004223680A patent/JP5021155B2/ja not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6221915B1 (en) | Pharmaceutical compositions | |
| ES2226435T3 (es) | Metodos de uso y composiciones que comprenden inhibidores de la recaptacion de dopamina. | |
| ES2329971T3 (es) | Composicion farmaceutica para la liberacion controlada de paracetamol. | |
| US11813247B2 (en) | NK-1 antagonist compositions and methods for use in treating depression | |
| US12521374B1 (en) | Combination therapy for a dopamine agonist | |
| TW200418474A (en) | Method of treating post-operative nausea and vomiting | |
| MXPA02003969A (es) | Tratamiento de desordenes del sueno por medio del uso de desloratadina. | |
| AU2008259864B2 (en) | Methods and compositions for administration of Oxybutynin | |
| CA2508611A1 (en) | Compositions of non-steroidal anti-inflammatory drugs, decongestants and anti-histamines | |
| JP2006515299A5 (enExample) | ||
| CA3071377C (en) | Compositions and methods for improving muscle weakness in patients suffering from myasthenia gravis and other myasthenic syndromes | |
| CA2846340A1 (en) | Treatment of symptoms associated with female gastroparesis | |
| JP2008100924A (ja) | 総合感冒薬組み合わせ製剤 | |
| M Farber et al. | Design and development of a novel supportive care product for the treatment of sialorrhea in Parkinson’s disease | |
| US10610507B2 (en) | Methods for the treatment of sialorrhea | |
| CA3097332C (en) | Composition comprising pramipexole and 5ht3 antagonist for treating depression | |
| US20020035157A1 (en) | Pharmaceutical compositions | |
| JP2004026810A (ja) | 鼻炎用組成物 | |
| WO2025096942A1 (en) | Trimeprazine for use in treating pain associated with trigeminal neuralgia | |
| TW200906406A (en) | Use of a compound that is a neurokinin A NK2 receptor antagonist for the preparation of medicaments for use in the prevention and treatment of sexual dysfunctions | |
| HK40014066A (en) | Therapies for the treatment of lidocaine-ineffective and hypokalemic conditions |